CSV February 23, 2023 through February 23, 2025 All Errata for USP–NF How to use

×

How to Use

- **Searching:** Type keyword in search field at top of page. Search by all or part of a monograph title. For searches using multiple criteria, you will find items that match each of the specified criteria unless quotation marks are used.
    - For example, a search on Aminosalicylic Acid Tablets will result in anything that contains “Aminosalicyclic” OR “Acid” OR “Tablets”
    - A search for “Aminosalicylic Acid Tablets” will result in anything that specifically contains “Aminosalicylic Acid Tablets”
- **Sorting:** Click on any column header title to sort alphabetically or chronologically in ascending or descending order. Note: the page load column is sorted alphabetically so that a number is ordered by first digit vs. by the actual number; thus, numbers will not always be in order.
    - For example, page 2178 will come before page 74 on a page sort.
- **Downloading:** You can download the Errata table in Comma-separated Value (.csv). The download will include the Errata that you have filtered on.
- **Importing:**You will need to import the file into Excel or Open Office with UTF-8 encoding, as opposed to simply opening it. To import, open Excel or Open Office and select import from the File drop-down. Depending on the version you are using, you should be presented with import formatting options to include UTF-8 as one of the first steps. Importing via UTF-8 should eliminate odd character conversions.

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
POWDERED	COMPOSITION	*USP37–NF32*	5456	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 4 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
HOLY BASIL LEAF	/*Content of Triterpenes*							*Standard solution B*: Change 0.45-?L to: 0.45-?m
PHENYTOIN SODIUM INJECTION	OTHER COMPONENTS/*Alcohol and Propylene Glycol Content*	*First Supplement to USP37–NF32*	6684	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3 of *Standard solution*: Change *Internal standard stock solution* to: *Internal standard solution*
ACETAMINOPHEN SUPPOSITORIES	ASSAY/*Procedure*	*USP37–NF32*	1567	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 6 of *Sample stock solution*: Change add 30 mL of hexane, to: add 30 mL of solvent hexane, AND Line 10 of *Sample stock solution*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								wash the hexane to: wash the solvent hexane
PSEUDOEPHEDRINE HYDROCHLORIDE, CARBINOXAMINE MALEATE, AND DEXTROMETHORPHAN HYDROBROMIDE ORAL SOLUTION	*Microbial enumeration tests* <*61*> and *Tests for specified microorganisms* <*62*>	*USP37–NF32*	4486	30-May-2014	1-Jun-2014	*USP38–NF33*	*USP38–NF33*	Line 3: Change does not exceed 100 per g, the total combined molds and yeasts count does not exceed 10 per g, to: does not exceed 10^2 cfu/g, the total combined molds and yeasts count does not exceed 10^1 cfu/g,
ANTIBIOTICS—MICROBIAL ASSAYS	Turbidimetric Method	*USP36–NF31*	76	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 9 of Paragraph 2 of *Analysis*: Change or a water bath maintained at

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								the temperature specified in *Table 8* and for the time specified in *Table 11*. to: or a water bath maintained at 36.0° –37.5° for the time specified in *Table 11*.
ONDANSETRON ORAL SOLUTION	*Related compounds*	*USP36–NF31*	4586	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Procedure*: Change $(293.36/329.82)10{,}000(1 / F)(1 / V)(C_S / C_A)(r_i / r_S)$ to: $(293.36 / 329.83)10{,}000(1 / F)(1 / V)(C_S / C_A)(r_i / r_S)$ AND Line 8 of *Procedure*: Change 329.82 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ATROPINE SULFATE INJECTION	ASSAY/ *Procedure*	*First Supplement to USP36–NF31*	5950	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	329.83 Line 1 of *Buffer*: Change Dissolve 4.1 g of sodium acetate and to: Dissolve 4.1 g of anhydrous sodium acetate and
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS	COMPOUNDING FACILITIES	*Revision Bulletin (Official January 01, 2014)*	Online	28-Mar-2014	1-Apr-2014	*Second Supplement to USP37–NF32*	*Second Supplement to USP37–NF32*	Line 4 of Paragraph 4: Change (see the *General Notices and Requirements, Preservation, Packaging, Storage, and Labeling, Storage Temperature and Humidity*; to: (see *Packaging and Storage Requirements <659>*;
CLINDAMYCIN	ASSAY/	*USP36–NF31*	3031	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
PALMITATE HYDROCHLORIDE	*Procedure*							*Acceptance criteria*: Change NLT 540 ?g to: NLT 540 ?g/mg
THALIDOMIDE CAPSULES	*Dissolution <711>*	*USP36–NF31*	5347	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	After the *Test solution* section: Add to: *Chromatographic system*—Prepare as directed in the *Assay* under *Thalidomide*.
CALCIUM SULFATE	ASSAY/ *Procedure*	*First Supplement to USP36–NF31*	Online	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 14 of *Analysis*: Change Result = [(*V* × *N* × *F*)/*W*] × 100 to: Result = [(*V* × *M* × *F*)/*W*] × 100 AND Line 15 of *Analysis*: Change *V* = volume of titrant consumed by the Sample

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(mL) *N* = actual normality of the titrant (mEq/mL) *F* = equivalency factor, 136.14 mg/mEq to: *V* = volume of *Titrant* consumed by the *Sample* (mL) *M* = actual molarity of the *Titrant* (mM/mL) *F* = equivalency factor, 136.14 mg/mM
Sodium Sulfite, Anhydrous	RE AGEN TS/*Reagent Specifications*	*USP36–NF31*	1196	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 2: Change [7753-83-7] to: [7757-83-7]
ONDANSETRON ORAL SOLUTION	*Assay*	*USP36–NF31*	4586	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Procedure*: Change (293.36/329.82) $100(C/V)(r_U / r_S)$ to: (293.36 / 329.83)100(*C* /

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								V)(r_U / r_S) AND Line 8 of *Procedure*: Change 329.82 to: 329.83
BUTYLPARABEN	IMPURITIES/*Related Substances/ Chromatographic system*	*Second Supplement to USP36–NF31*	6551	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	After the *Column* section: Add *Column temperature*: 35°
PHARMACEUTICAL COMPOUNDING—NONSTERILE PREPARATIONS	STABILITY CRITERIA AND BEYOND-USE DATING/*General Guidelines for Assigning Beyond-Use Dates*	*Revision Bulletin (Official January 01, 2014)*	Online	28-Mar-2014	1-Apr-2014	*Second Supplement to USP37–NF32*	*Second Supplement to USP37–NF32*	Line 7 of Paragraph 1: Change (see the *General Notices and Requirements, Preservation, Packaging, Storage, and Labeling*) to: (see <659>)
MELPHALAN TABLETS	*Dissolution <711>*	*USP36–NF31*	4232	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Mobile phase*: Change Prepare a

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								filtered and degassed mixture of water, acetonitrile, ammonium acetate, glacial acetic acid, and triethylamine (1 500:500:2:2:0.4). Make adjustments if necessary (see *System Suitability* under *Chromatography* <621>). to: Transfer 2 grams of ammonium acetate, 2 mL of glacial acetic acid, and 0.4 mL of triethylamine to a suitable flask containing 1500 mL of water and 500 mL of acetonitrile. Stir

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								until all solids are dissolved and well mixed, then filter and degas.
THIMEROSAL	IMPURITIES/*Mercury Ions*	*USP36–NF31*	5368	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 19 of *Analysis*: C_S = concentration of mercuric chloride in the *Standard solution* (mg/mL) to: C_S = concentration of mercuric chloride in *Sample solution B* (mg/mL)
ONDANSETRON INJECTION	*Assay*	*Second Supplement to USP36–NF31*	Online	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 7 of *Procedure*: Change (293.36 / 329.82)(25*C* / *V*)(r_U / r_S) to: (293.36 / 329.83)(25*C* / *V*)(*r*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								$_U$/ r_S) AND Line 8 of *Procedure*: Change 329.82 to: 329.83
MAGNESIUM ALUMINUM SILICATE	IM PUR ITIES/*Arsenic, Method I <211>*	*USP36–NF31*	2073	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Standard preparation*: Change Prepare as directed in the chapter. to: Transfer 5.0 mL (5 ?g of arsenic) of the *Standard Arsenic Solution* to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Delete: *Control preparation*: Transfer 5.0 mL

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								(5 ?g of As) of the *Standard preparation* to a 25-mL volumetric flask, and add dilute hydrochloric acid (1:25) to volume. AND Line 1 of *Acceptance criteria*: Change the absorbance due to any red color from the *Test preparation* does not exceed that produced by the *Control preparation*. to: the absorbance due to any red color from the *Test preparation* does not exceed that

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								produced by the *Standard preparation*.
SODIUM ACETATE	IM PURITIES/*Inorganic Impurities*/*Potassium*	*USP36–NF31*	5147	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 1 of *Sample solution*: Change Equivalent to 600 mg/mL of anhydrous sodium acetate to: Dissolve the equivalent of 3 g of anhydrous sodium acetate in 5 mL of water. AND Line 1 of *Analysis*: Change To 5 mL of *Sample solution* add to: To the *Sample solution* add
CARBIDOPA AND LEVODOPA	ASSAY	*Second Supplement to USP36–NF31*	6580	28-Mar-2014	1-Apr-2014	*USP38–NF33*	*USP38–NF33*	Line 2 of *Procedure*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
ORALLY DISINTEGRATING TABLETS								Inject the *Sample solution* within 2 h of preparation. Protect the volumetric solutions from light. to: Protect the volumetric solutions from light.
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH/ *Molybdenum, Method 1*	*Second Supplement to USP36–NF31*	6372	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Standard solutions*: Change 2.0 to: 5.0
GLYCERYL TRISTEARATE	IDENTIFICATION/*Fatty Acid Composition*	*USP36–NF31*	2033	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 19 of *Analysis*: Change Result = $[(F_{MC} \times P_{FA1} \times A_{MC})/(P_{MC} \times A_{FA1})] \times 100$ to: Result = $(F_{MC} \times P_{FA1} \times A_{MC})/(P_{MC} \times A_{FA1})$

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DICLOFENAC SODIUM DELAYED-RELEASE TABLETS	IMPURITIES/*Organic Impurities/Procedure*	*USP36–NF31*	3221	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 22 of *Analysis*: Change r_S = peak response for each impurity from the *Standard solution* to: r_S = peak response of diclofenac related compound A from the *Standard solution*
TIZANIDINE TABLETS	IMPURITIES/*Organic Impurities/Procedure*	*USP36–NF31*	5408	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 9 of *Sample solution*: Change 45-µm or finer pore size to: 0.45-µm or finer pore size
OXALIPLATIN INJECTION	IMPURITIES/*Limit of Oxalic Acid*	*First Supplement to USP36–NF31*	6033	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of *Analysis*: Change Calculate the

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								percentage of each impurity to: Calculate the percentage of oxalic acid
WATER-SOLUBLE VITAMINS WITH MINERALS CAPSULES	STRENGTH/*Molybdenum, Method 1*	*Second Supplement to USP36–NF31*	6479	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Standard solutions*: Change 2.0 to: 5.0
CEFTAZIDIME FOR INJECTION	*Assay*	*USP36–NF31*	2887	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 6 of *Procedure*: Change 250,000[*C*/*W* (100 ? *m* ? *s*)](*r*$_U$ / *r*$_S$) to: 25,000{*C*/[*W* (100 ? *m* ? *s*)]}(*r*$_U$ / *r*$_S$)
RIBOFLAVIN 5?-PHOSPHATE SODIUM	IMPURITIES/*Free Riboflavin and Riboflavin Diphosphates*	*USP36–NF31*	5037	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Emission wavelength*: Change 530 nm to: 530 nm (monochromator-based

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								detector) or 470 nm (filtered-type detector)
CYCLOMETHICONE	ASSAY/ *Procedure*/*System suitability*	*First Supplement to USP36–NF31*	5909	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Suitability requirements*: Change *Relative standard deviation*: NMT 2.0% for cyclomethicone 4, cyclomethicone 5, and cyclomethicone 6, *Standard solution A*, *Standard solution B*, and *Standard solution C* to: *Relative standard deviation*: NMT 2.0% for cyclomethicone 4, *Standard solution A*; NMT 2.0% for

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								cyclomethicone 5, *Standard solution B*; NMT 2.0% for cyclomethicone 6, *Standard solution C*
OIL- AND WATER-SOLUBLE VITAMINS WITH MINERALS ORAL SOLUTION	STRENGTH/*Chromium*	*Second Supplement to USP36–NF31*	6399	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 13 of *Analysis*: Change *C* = concentration of chromium in the *Standard solution* (µg/mL) to: *C* = concentration of chromium in the *Sample solution* (µg/mL)
ANAGRELIDE HYDROCHLORIDE	ASSAY/*Procedure*/*Chromatographic system*/*System suitability*	*USP36–NF31*	2500	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 2 of *Suitability requirements*: Change *Column efficiency*: NMT to: *Column efficiency*: NLT
DILTIAZEM HY	IM	*USP36–NF31*	3258	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second*	Line 21 of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
DROCHLORIDE	PURITIES/*Organic Impurities*						*Supplement to USP37–NF32*	*Analysis*: Change r_S = response of each impurity peak from the *Standard solution* to: r_S = peak response of desacetyl diltiazem from the *Standard solution*
VANCOMYCIN HYDROCHLORIDE	SPECIFIC TESTS/ *Composition of Vancomycin*	*USP36–NF31*	5543	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 28 of *Analysis*: Change Result = $[(r_I/(D \times r_B) + r_A)] \times 100$ to: Result = $\{r_I/[(D \times r_B) + r_A]\} \times 100$
CONTAINERS GLASS-EVALUATION OF INNER SURFACE DURABILITY	EVALUATION OF THE INNER SURFACED URABILITY/*Aggressive*	*Second Supplement to USP36–NF31*	6221	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Row 1 of Column 3 of *Table 4*: Change 3% Citric Acid pH 8.0 to:

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
	Screening Conditions							3% Sodium Citrate pH 8.0
ISOPROPYL ALCOHOL	ASSAY/ *Procedure*	*Second Supplement to USP36–NF31*	6638	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 17 of *Chromatographic system*: Change *Linear velocity*: 35 cm/s to: *Flow rate*: 2.3 mL/min AND Row 2 of Column 1 of *Table 2*: Change Diethyl ether to: Ethyl ether
CLARITHROMYCIN	ASSAY/ *Procedure*/*System suitability*	*USP36–NF31*	3016	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Samples*: Change *Standard solution 2* and *Standard solution 4* to: *Standard solution 1*, *Standard solution 2*, and

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Standard solution 4 AND Line 13 of *Suitability requirements*: Change *Relative standard deviation*: NMT 1.5%, *Standard solution 2* to: *Relative standard deviation*: NMT 1.5%, *Standard solution 1*
RISPERIDONE TABLETS	*Dissolution <711>*	*USP36–NF31*	5065	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 4 of *Chromatographic system*: Change Chromatograph the *Standard solution* and the *Test solution* as directed for *Procedure*: to: Chromatograph the *Standard*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								solution as directed for *Procedure*:
ATOMOXETINE HYDROCHLORIDE	IMPURITIES/*Organic Impurities, Procedure 2*	*First Supplement to USP36–NF31*	5947	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 5 of *System suitability solution*: Change dissolving the Reference Standards in ethanol, to: dissolving the Reference Standards in absolute alcohol, AND Line 2 of *Sample solution*: Change dissolving it in ethanol, to: dissolving it in absolute alcohol,
OIL- AND WATER-SOLUBLE	CONTAMINANTS	*Second Supplement to*	6399	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to*	Add the test: *Absence of*

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
VITAMINS WITH MINERALS ORAL SOLUTION		*USP36–NF31*					*USP37–NF32*	*Specified Microorganisms* <2022>: Meet the requirements of the tests for the absence of *Salmonella species*, *Escherichia coli*, and *Staphylococcus aureus*
CANDESARTAN CILEXETIL	ASSAY/ *Procedure*	*USP36–NF31*	2774	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Analysis*: Change Titrate with 8 mL of 0.1 N to: Titrate with 0.1 N
FENTANYL	IMPURITIES/*Organic Impurities/Acceptance criteria*	*USP36–NF31*	3554	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Footnote f of Table 2: Change *N*-Phenyl-*N*-[1-(2-phenylethyl)-4-piperidinyl] acetanilide hydrochloride,

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								or acetyl fentanyl. to: *N* -(1-Phenethylpiperidin-4-yl)-*N* -phenylacetamide.
VANCOMYCIN HYDROCHLORIDE FOR INJECTION	SPECIFIC TESTS/*Content of Vancomycin*	*USP36–NF31*	5546	31-Jan-2014	1-Feb-2014	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 27 of *Analysis*: Change Result = $[r_I/(D \times r_B) + r_A] \times 100$ to: Result = $\{r_I/[(D \times r_B) + r_A]\} \times 100$
LACTATED RINGER'S INJECTION	*Definition*	*USP36–NF31*	5055	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 13: Change 408.0 mg of chloride to: 428.0 mg of chloride
BUFFER SOLUTIONS	*4. Standard Buffer Solutions/4.1 Preparation*	*Second Supplement to USP36–NF31*	6244	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of 4. *Boric Acid and Potassium Chloride 0.2 M*: Change

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								12.73 g/L of boric acid to: 12.37 g/L of boric acid
DIVALPROEX SODIUM EXTENDED-RELEASE TABLETS	PERFORMANCE TESTS/ *Dissolution <711>/Test 5*	*Second Supplement to USP36–NF31*	6592	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 3 of *Acid stage sample solution*: Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size. AND Line 3 of *Buffer stage sample solution*: Change suitable filter of 45-µm pore size. to: suitable filter of 0.45-µm pore size.
ALMOND OIL	SPECIFIC TESTS/*Sterol Composition*	*USP36–NF31*	1877	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Row 9 of *Table 2*: Change ?7-Stigmastenol

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								?3.0% to: ?7-Stigmastenol ?3.0%
FLUOCINONIDE TOPICAL SOLUTION	*Alcohol content*	*USP36–NF31*	3618	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Standard solution*: Change Dilute 20.0 mL of USP Alcohol to: Dilute 20.0 mL of alcohol
MINERAL OIL	SPECIFIC TESTS	*USP36–NF31*	4372	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Viscosity—Capillary Viscometer Methods <911>*: Change 34.5 and 150.0 $mm^2 \cdot s^{?1}$ to: 34.5–150.0 $mm^2 \cdot s^{?1}$
ATROPINE SULFATE	SPECIFIC TESTS/*Optical Rotation, Specific Rotation* <781>	*First Supplement to USP36–NF31*	5948	22-Nov-2013	1-Dec-2013	*USP38–NF33*	*Second Supplement to USP37–NF32*	Line 1 of *Sample solution*: Change 0.1 mg/mL in water to: 0.1 g/mL of

Monograph Title	Section	Source Publication	Page Number	Errata Post Date Sort ascending	Errata Official Date	Target Errata Print Publication	Target Online Fix Publication	Description
								Atropine Sulfate in water

Pagination

- First page « First
- Previous page ‹ Previous
- …
- Page 30
- Page 31
- Page 32
- Page 33
- Page 34
- Page 35
- Page 36
- Page 37
- Page 38
- …
- Next page Next ›
- Last page Last »